Amrecibart and cenvacibart cut catheter clots in a trial including cancer patients

In a trial of 194 people having a catheter placed, including patients with active cancer, 20% who received either drug had a clot by day 14, compared with 43% who received placebo. No major bleeding occurred.

“A single infusion of amrecibart or cenvacibart reduced the incidence of venous thromboembolism following PICC insertion, suggesting FXI inhibition at the A2 or catalytic domain as a promising prophylactic strategy for contact-mediated thrombosis.”

Why it matters. A mid-stage trial in cancer. Good results at this stage usually still need a larger trial before approval.

Review reports advances in China’s lung cancer drug development

A review of cancer drug development in China from 2015 to 2025 found globally relevant advances in lung cancer. It says the scale of development alone will not ensure global impact.

Why it matters. A research finding about lung cancer.

Bladder cancer DNA testing rose, but pathology drove treatment decisions

In a study of 4,533 people with bladder cancer who had surgery, use of blood DNA testing increased by 16% per calendar quarter. Detectable DNA was linked to more follow-up treatment before adjustment, but the link was no longer significant after accounting for other factors.

“Postcystectomy circulating tumour DNA (tumour DNA found in the blood) testing increased rapidly, particularly among patients with high-risk pathology.”

Why it matters. Based on data or samples from people with bladder cancer. It is not a treatment trial.